New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...

BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...

Please provide your email address to receive an email when new articles are posted on . No significant differences were found in risk for serious infection among ocrelizumab age groups.

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity and ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche’s top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS) - ...